

# SARS CoV-2 infection screening via the exhaled breath fingerprint obtained by FTIR spectroscopic gas phase analysis: A proof of concept

Lorena Díaz de León Martínez<sup>a,1,\*</sup>, Johannes Glöckler<sup>a,1</sup>, Boris Mizaikoff<sup>a,b</sup>

<sup>a</sup>Institute of Analytical and Bioanalytical Chemistry, Ulm University, Albert-Einstein-Allee 11, 89081 Ulm, Germany; <sup>b</sup>Hahn-Schickard Institute for Microanalysis Systems, Sedanstrasse 14, 89077 Ulm, Germany

\*Corresponding author. E-mail address: [lorena.diaz-de-leon@uni-ulm.de](mailto:lorena.diaz-de-leon@uni-ulm.de) (L. Díaz de León-Martínez). <sup>1</sup>Both authors equally contributed to this work.

## Introduction

The COVID-19 pandemic remains a global challenge now with the **long-COVID** arising. Mitigation measures focused on case counting, assessment and determination of variants and their likely targets of infection and transmission, the pursuit of drug treatments, use and enhancement of masks, social distancing, vaccination, post-infection rehabilitation, and **large population screening**. The latter is of utmost importance given the current scenario of infections, reinfections, and long-term health effects.

Hence, research toward **screening platforms** has been emphasized to provide more **sensitive, specific, and reliable** tests that are **accessible** to the entire population. Thereby, the **prognosis** of the disease can be assessed along with a subsequent **health follow-up** of patients with **sequelae of COVID-19**.


**AIM:** The simulation of **exhaled breath of COVID-19** patients by evaluation of three identified COVID-19 indicator **breath biomarkers** (acetone (ACE), acetaldehyde (ACH) and nitric oxide (NO)) via **gas-phase infrared spectroscopy** using substrate-integrated hollow wave-guide (iHWG) technology as a proof-of-concept principle for the detection of the infected patient **exhaled breath fingerprints** and subsequent follow-up

## Results


## Calibration and validation

**Table 1.** Validation parameters for each of the investigated biomarkers.

Parameter	Breath Biomarkers		
	NO	ACE	ACH
LOD (ppm)	6.42	13.81	9.22
LOQ (ppm)	42.26	52.57	69.23
Linearity (r)	0.998	0.999	0.999
Sensitivity (CI 95%)	0.0001±0.01	0.001±0.001	0.002±0.001
Precision	Repeatability	3.9-10.4	2.1-17.6
	Reproducibility (%RSD)	8.6-10.6	3.1-12.4



## Methodology



### Calibration and validation


- 1.1) Biomarkers: ACE, ACH, NO
- 1.2) 4% of CO<sub>2</sub>
- 1.3) 58% r.h. @ 36°C
- 1.4) LOD, LOQ, linearity (r), sensitivity (m), precision (repeatability and reproducibility)

### Measurements


- 2.1) Experimental setup (Figure 1)
- 2.2) Automatic operation
- 2.3) Total gas flow: 500 mL/min
- 2.4) Stopped-flow mode
- 2.5) Set-up purge (synthetic air)
- 2.6) Background measurement
- 2.7) Gas mixture measurement

### Data acquisition

- 3.1) Range: 4000 to 700 cm<sup>-1</sup>
- 3.2) Resolution: 2 cm<sup>-1</sup>
- 3.3) Averaging 64 scans



## Gas Mixture Evaluation



## Acknowledgement

The IRENE project is supported by the Ministerium für Wissenschaft, Forschung und Kunst (MWK) in Baden-Württemberg, Germany within the program "Sonderförderlinie COVID-19".